Targets › PTGS1
59 programs from 54 companies in 121 trials: 46 Phase 2, 30 Phase 4, 25 Phase 1, 20 Phase 3; Other, Oncology, Immunology; next expected readout Dec 2026.
Dual cyclooxygenase and peroxidase that plays an important role in the biosynthesis pathway of prostanoids, a class of C20 oxylipins mainly derived from arachidonate ((5Z,8Z,11Z,14Z)-eicosatetraenoate, AA, C20:4(n-6)), with a particular role in the inflammatory response. The cyclooxygenase activity oxygenates AA to the hydroperoxy endoperoxide prostaglandin G2 (PGG2), and the peroxidase activity reduces PGG2 to the…. (UniProt, P23219)
Open in Phaseline: the race on PTGS1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| The University of Texas Health Science Center, Houston | ALA 10% gel Muscle-type nicotinic acetylcholine receptor antagonist | HCRTR2, HCRTR1, CHRNA1, CHRNG, CHRNB1, CHRND, CHRNE, HTR2A, PTGS2, PTGS1 | Phase 4 | Anesthesia; Cleft Lip and Palate; Pancreatic Ductal Adenocarcinoma (PDAC); Stimulant Use Disorder … | Dec 2026 |
| Changhai Hospital | Indomethacin Cyclooxygenase inhibitor | PTGS2, PTGS1 | Phase 4 | Post-ERCP Pancreatitis | Dec 2026 |
| University of Calgary | CBD 100 mg OD Interleukin-23 inhibitor | CNR1, PLAT, IL12B, IL23A, ADRB2, HTR2A, NR3C1, TNF, PTGS2, PTGS1 | Phase 4 | Copd; Ehlers-Danlos Syndrome; Crohn Disease; Vasovagal Syncope … | Dec 2026 |
| Henry Ford Health System | Ketorolac Cyclooxygenase inhibitor | PTGS2, PTGS1 | Phase 4 | Femoracetabular Impingement; Narcotic Use | Dec 2026 |
| Beijing Friendship Hospital | Flurbiprofen Cyclooxygenase inhibitor | PTGS2, PTGS1 | Phase 4 | Opioid-free Anesthesia | Dec 2026 |
| Massachusetts General Hospital | Ketorolac Cyclooxygenase inhibitor | PTGS2, PTGS1 | Phase 4 | Orthopaedic Trauma | Dec 2026 |
| The University of Hong Kong | Ketorolac Cyclooxygenase inhibitor | PTGS2, PTGS1 | Phase 4 | Patella Fracture | Dec 2026 |
| Xiangya Hospital of Central South University | Acetaminophen-Mannitol Injection Non-selective COX inhibitor (analgesic) with osmotic agent | PTGS1, PTGS2 | Phase 4 | Postoperative Delirium | Jan 2027 |
| University of Chicago | Ketorolac Tromethamine Cyclooxygenase inhibitor | PTGS2, PTGS1 | Phase 4 | Surgery, Upper Extremity | Feb 2027 |
| University of Maryland St. Joseph Medical Center | Ketorolac Tromethamine Cyclooxygenase inhibitor | PTGS2, PTGS1 | Phase 4 | Lumbar Spinal Fusion | Jun 2027 |
| Northwestern University | Naproxen Cyclooxygenase inhibitor | PTGS2, PTGS1 | Phase 4 | Osteoarthritis, Knee; Opioid Use | Jun 2027 |
| Emory University | Ketorolac Cyclooxygenase inhibitor | PTGS2, PTGS1 | Phase 4 | Osteoarthritis | Jul 2027 |
| Jessica D. Kresowik | Ketorolac Cyclooxygenase inhibitor | PTGS2, PTGS1 | Phase 4 | Infertility (IVF Patients) | Oct 2027 |
| Phoenix Children's Hospital | ketorolac Cyclooxygenase inhibitor | PTGS2, PTGS1 | Phase 4 | Congenital Heart Disease in Children | Oct 2027 |
| Thomas Jefferson University | Ketorolac Cyclooxygenase inhibitor | PTGS2, PTGS1 | Phase 4 | Cesarean Delivery | Dec 2027 |
| Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | bupivacaine-meloxicam (extended release) Local anesthetic (bupivacaine) combined with NSAID/COX inhibitor (meloxicam) | PTGS1, PTGS2 | Phase 4 | Periarticular Block | Jan 2028 |
| Peking Union Medical College Hospital | Indomethacin Cyclooxygenase inhibitor | PTGS2, PTGS1 | Phase 4 | Acute Pancreatitis | Jun 2028 |
| University of Colorado, Denver | ketorolac Cyclooxygenase inhibitor | PTGS2, PTGS1 | Phase 4 | Chronic Kidney Disease | Jun 2028 |
| Endeavor Health | Naproxen Sodium Cyclooxygenase inhibitor | PTGS2, PTGS1 | Phase 4 | Dysmenorrhea | Apr 2030 |
| Madigan Army Medical Center | Ketorolac Cyclooxygenase inhibitor | PTGS2, PTGS1 | Phase 4 | Low Back Pain | – |
| Instituto de Oftalmología Fundación Conde de Valenciana | Nepafenac Cyclooxygenase inhibitor | PTGS2, PTGS1 | Phase 4 | Epiphora | – |
| University of Alberta | Ketorolac Cyclooxygenase inhibitor | PTGS2, PTGS1 | Phase 3 | Pain Management | Dec 2026 |
| St. Louis University | Ketorolac Cyclooxygenase inhibitor | PTGS2, PTGS1 | Phase 3 | Bone Metastases | Dec 2026 |
| AFT Pharmaceuticals | Combogesic® IV Fixed-dose combination of acetaminophen and ibuprofen | PTGS1, PTGS2 | Phase 3 | Acute Pain | Mar 2027 |
| Centre Hospitalier Universitaire, Amiens | Ketoprofen (RP19583) Cyclooxygenase inhibitor | PTGS2, PTGS1 | Phase 3 | Acute Postoperative Pain; Non-steroidal Anti-inflammatory Drugs | Mar 2027 |
| NICHD Neonatal Research Network | indomethacin Cyclooxygenase inhibitor | PTGS2, PTGS1 | Phase 3 | Infant, Premature | May 2027 |
| Brainfarma Industria Química e Farmacêutica S/A | Dipyrone Cyclooxygenase inhibitor | PTGS2, PTGS1 | Phase 3 | Common Cold/Flu; Hematologic Test | Jun 2027 |
| The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Ketorolac Cyclooxygenase inhibitor | PTGS2, PTGS1 | Phase 3 | Aortic Dissection | Sep 2027 |
| The University of Hong Kong | Piroxicam Non-selective COX inhibitor | PTGS1, PTGS2 | Phase 3 | Contraception | Sep 2027 |
| SWOG Cancer Research Network | sulindac Cyclooxygenase inhibitor | PTGS2, PTGS1 | Phase 3 | Colorectal Neoplasms | Sep 2027 |
| Chinese University of Hong Kong | Indomethacin Cyclooxygenase inhibitor | PTGS2, PTGS1 | Phase 3 | Post ERCP Pancreatitis | May 2028 |
| University of Calgary | Ketorolac Tromethamine Cyclooxygenase inhibitor | PTGS2, PTGS1 | Phase 3 | Acute Pain | Jan 2029 |
| Weill Medical College of Cornell University | Ketorolac Cyclooxygenase inhibitor | PTGS2, PTGS1 | Phase 3 | Mechanical Ventilation | Jul 2029 |
| University of Miami | Ketorolac Cyclooxygenase inhibitor | PTGS2, PTGS1 | Phase 2 | Kidney Cancer | Dec 2026 |
| Emory University | Diclofenac Potassium Cyclooxygenase inhibitor | PTGS2, PTGS1 | Phase 2 | Advanced Lung Non-Small Cell Carcinoma | Jan 2027 |
| Massachusetts General Hospital | Omega 3 (EPA-enriched) Pro-resolving lipid mediator precursor; substrate for production of specialized pro-resolv | PTGS1, PTGS2, ALOX5 | Phase 2 | Treatment Resistant Depression | Mar 2027 |
| Jules Bordet Institute | Ketorolac Cyclooxygenase inhibitor | PTGS2, PTGS1 | Phase 2 | Early-stage Breast Cancer | Apr 2027 |
| Rush University Medical Center | Ketorolac Cyclooxygenase inhibitor | PTGS2, PTGS1 | Phase 2 | Pain Management | Apr 2027 |
| The Cleveland Clinic | Ketorolac Cyclooxygenase inhibitor | PTGS2, PTGS1 | Phase 2 | ACL - Anterior Cruciate Ligament Rupture | Jun 2027 |
| AHS Cancer Control Alberta | Mesalamine Arachidonate 5-lipoxygenase inhibitor; Peroxisome proliferator-activated receptor gamma agonist; Cyclooxygenase inhibitor | ALOX5, PPARG, PTGS2, PTGS1 | Phase 2 | Immune-related Adverse Event | Aug 2027 |
| NYU Langone Health | Sulfasalazine Arachidonate 5-lipoxygenase inhibitor; Cyclooxygenase inhibitor | ALOX5, PTGS2, PTGS1 | Phase 2 | Rheumatic Disease | Jan 2028 |
| Rutgers, The State University of New Jersey | Sulfasalazine Arachidonate 5-lipoxygenase inhibitor; Cyclooxygenase inhibitor | ALOX5, PTGS2, PTGS1 | Phase 2 | Preterm Birth | Jan 2028 |
| M.D. Anderson Cancer Center | Ketoprofen Cyclooxygenase inhibitor | PTGS2, PTGS1 | Phase 2 | Fibrosis Syndrome | Jul 2030 |
| Ann-Sofie Backman | Mesalamine Arachidonate 5-lipoxygenase inhibitor; Peroxisome proliferator-activated receptor gamma agonist; Cyclooxygenase inhibitor | ALOX5, PPARG, PTGS2, PTGS1 | Phase 2 | Lynch Syndrome | Sep 2032 |
| British University In Egypt | Diclofenac Sodium Cyclooxygenase inhibitor | PTGS2, PTGS1 | Phase 2 | Endodontic Disease | – |
| North American Consortium for Histiocytosis | INDOMETHACIN Cyclooxygenase inhibitor | PTGS2, PTGS1 | Phase 2 | Langerhans Cell Histiocytosis | – |
| Duke University | Sulindac Cyclooxygenase inhibitor | PTGS2, PTGS1 | Phase 2 | IPMN | – |
| University of Zurich | Sulfasalazine Arachidonate 5-lipoxygenase inhibitor; Cyclooxygenase inhibitor | ALOX5, PTGS2, PTGS1 | Phase 1 | Glioblastoma | Dec 2026 |
| Assistance Publique - Hôpitaux de Paris | Sulfasalazine Arachidonate 5-lipoxygenase inhibitor; Cyclooxygenase inhibitor | ALOX5, PTGS2, PTGS1 | Phase 1 | Acute Myeloid Leukemia | Dec 2026 |
| University of Texas Southwestern Medical Center | Ketorolac Cyclooxygenase inhibitor | PTGS2, PTGS1 | Phase 1 | Post Operative Pain | Apr 2027 |
| Caribou Biosciences | Lornoxicam (CB-011) Cyclooxygenase inhibitor | PTGS2, PTGS1 | Phase 1 | Relapsed/Refractory Multiple Myeloma | Dec 2027 |
| Sana Biotechnology | Lornoxicam (SC291) Cyclooxygenase inhibitor | PTGS2, PTGS1 | Phase 1 | Lupus Erythematosus; Non Hodgkin's Lymphoma; Non Hodgkin Lymphoma; Preterm Premature Rupture of Membrane … | Dec 2027 |
| National Institute of Mental Health (NIMH) | [11C]MC1 Radioligand for cyclooxygenase-2 (COX-2) imaging | PTGS2, PTGS1 | Phase 1 | Parkinson's Disease; Depression | Apr 2029 |
| Satish R. Raj | Indomethacin Cyclooxygenase inhibitor | PTGS2, PTGS1 | Phase 1 | Tachycardia | Dec 2029 |
| Rockefeller University | Naproxen Sodium Cyclooxygenase inhibitor | PTGS2, PTGS1 | Phase 1 | Fanconi Anemia | Oct 2030 |
| Haiphong University of Medicine and Pharmacy | DW-1021 Fixed-dose combination of nonsteroidal anti-inflammatory drug and opioid analgesic | PTGS1, PTGS2, OPRM1 | Phase 1 | Healthy Volunteer | – |
| ZetrOZ | Diclofenac Cyclooxygenase inhibitor | PTGS2, PTGS1 | Phase 1 | Bone Fracture; Osteoarthritis; Blood Gas Analysis; Elbow Pain | – |
| Haiphong University of Medicine and Pharmacy | Pelubiprofen Non-selective cyclooxygenase (COX) inhibitor | PTGS1, PTGS2 | Phase 1 | Healthy Volunteers | – |
| New Valley University | ketoprofen Cyclooxygenase inhibitor | PTGS2, PTGS1 | Phase 1 | Knee Osteoarthritis | – |
Pain Management (2) Osteoarthritis (2) Acute Pain (2) Metastatic Colorectal Cancer (2) Musculoskeletal Injury (2) Microscopic Colitis (2) Investigating the Importance of the Subjective Psychedelic Experience (2) Common Cold/Flu (2) Kidney Cancer (1) Bone Fracture (1) Blood Gas Analysis (1) Elbow Pain (1)
small molecule (48), mixed (7), protein or peptide (2)
University of Calgary (2) Haiphong University of Medicine and Pharmacy (2) Massachusetts General Hospital (2) Emory University (2) The University of Hong Kong (2) Rush University Medical Center (1) University of Miami (1) ZetrOZ (1) Centre Hospitalier Universitaire, Amiens (1) SWOG Cancer Research Network (1) University of Zurich (1) National Institute of Mental Health (NIMH) (1) Instituto de Oftalmología Fundación Conde de Valenciana (1) University of Texas Southwestern Medical Center (1) Caribou Biosciences (1) Sana Biotechnology (1) Weill Medical College of Cornell University (1) Chinese University of Hong Kong (1) Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) (1) NICHD Neonatal Research Network (1)
PTGS2 (59) ALOX5 (7) HTR2A (2) PPARG (2) OPRM1 (1) CNR1 (1) PLAT (1) IL12B (1) IL23A (1) ADRB2 (1) NR3C1 (1) TNF (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.